Business
MGC Pharma strikes exclusive world-wide product distribution agreement – Stockhead
Three-year deal with Swiss PharmaCan is for world-wide distribution of its anti-inflammatory product ‘We are very happy with the successful cooperation between…
Link copied toclipboard
- Three-year deal with Swiss PharmaCan is for world-wide distribution of its anti-inflammatory product
- ‘We are very happy with the successful cooperation between MGC and Swiss PharmaCan’ – Swiss PharmaCan CEO
- MGC Pharma to dispatch 40,000 units per quarter of its product to Swiss PharmaCan
Biopharma company MGC Pharmaceuticals (ASX:MXC) has stuck a worldwide supply and distribution agreement for its anti-inflammatory medicinal cannabis product that can be used to treat COVID-19.
…
Continue Reading
-
Noosa News15 hours agoPill checking to resume in Queensland months after government axed funding
-
Business18 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
Noosa News23 hours agoBob Katter threatens to punch Nine reporter Josh Bavas during anti-immigration press conference
-
Business17 hours agoBrokers name 3 ASX shares to buy today 29 August 2025